Expansion of Web-Based Ordering for Veterinary Hospitals Through MP+, an Ordering Platform
First written in FY2018-Q2. 11 of 13 entries say "Restated". Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022RestatedAnnual report
「Sales performed solidly, supported by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus). In addition to conventional product distribution and information provision, the company is working to build a new sales model that integrates distribution and marketing functions.」
The company continues to expand the use of MP+ and build a sales model integrating distribution and marketing functions. - FY2022-Q1AdvancedAnnual report
「Against this backdrop, MP AGRO Co., Ltd. (Kitahiroshima, Hokkaido), a wholly owned consolidated subsidiary, achieved steady sales growth through intensified efforts involving products sold exclusively in Japan and the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus). In addition to conventional product distribution and information provision, the company is working to build a new sales model that integrates distribution and marketing functions.」
In addition to expanding the use of MP+, the company has clearly stated its intention to build a new sales model integrating product distribution, information provision and marketing functions. - FY2021RestatedAnnual report
「Sales of veterinary pharmaceuticals performed solidly, despite the impact of widespread avian influenza infections in the livestock market, supported by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus), in the companion animal market.」
The company continues to support veterinary hospitals by expanding the use of MP+. - FY2021-Q2RestatedAnnual report
「Sales of veterinary pharmaceuticals performed solidly, supported by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus).」
The company continues to support veterinary hospitals by expanding the use of MP+. - FY2021-Q1RestatedAnnual report
「Sales of veterinary pharmaceuticals performed solidly, supported by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus).」
The company continues to support veterinary hospitals by expanding the use of MP+. - FY2020-Q3RestatedAnnual report
「Sales of veterinary pharmaceuticals performed solidly, supported by active initiatives centered on vaccines and feed additives in the livestock market, and by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus), and initiatives involving products developed in-house in the companion animal market.」
The company continues its initiatives to support veterinary hospitals, including expanding the use of MP+. - FY2020-Q2RestatedAnnual report
「Sales of veterinary pharmaceuticals performed steadily, supported by active initiatives centered on vaccines and feed additives in the livestock market, and by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus), and initiatives involving products developed in-house in the companion animal market.」
The company continues its initiatives to support veterinary hospitals, including expanding the use of MP+. - FY2019-Q3RestatedAnnual report
「Sales of veterinary pharmaceuticals performed steadily, supported by active initiatives centered on vaccines and feed additives in the livestock market, and by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus), and the exclusive sale of skincare products in the companion animal market.」
The company continues its initiatives to support veterinary hospitals, including expanding the use of MP+. - FY2019-Q2RestatedAnnual report
「Sales of veterinary pharmaceuticals performed steadily, supported by active initiatives centered on vaccines and feed additives in the livestock market, and by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+ (MP Plus), and initiatives involving exclusive skincare products in the companion animal market.」
The company continues its initiatives to support veterinary hospitals, including expanding the use of MP+. - FY2019-Q1RestatedAnnual report
「Business performed solidly, supported by intensified efforts in the Kanto region, Japan's largest companion animal market, and the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+® (MP Plus), among other factors.」
The company continues to expand the use of MP+ and intensify its efforts in the Kanto region. - FY2018RestatedAnnual report
「Business performed steadily, supported by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+® (MP Plus), among other factors.」
The company continues its initiatives to support veterinary hospitals, including expanding the use of MP+. - FY2018-Q3RestatedAnnual report
「Sales of veterinary pharmaceuticals performed steadily, supported by active initiatives centered on vaccines and feed additives in the livestock market, growth in treatments for skin diseases and products related to aging in the companion animal market, and the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+® (MP Plus), among other factors.」
The company continues its initiatives to support veterinary hospitals, including expanding the use of MP+. - FY2018-Q2First statedAnnual report
「Business performed steadily, supported by the expanding use of our proprietary web-based ordering and information system for veterinary hospitals, MP+® (MP Plus), among other factors.」
The company described the expanding use of MP+, its proprietary web-based ordering and information system for veterinary hospitals, as a new operational development.